PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Participate in Upcoming Virtual Investor Conferences in March
ERYTECH to Participate in Upcoming Virtual Investor Conferences in March Lyon (France) and Cambridge, MA (U.S.), February 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH to Present at the 2021 BIO CEO & Investor Conference
ERYTECH to Present at the 2021 BIO CEO & Investor Conference Lyon (France) and Cambridge, MA (U.S.), February 10, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood
View HTML
Toggle Summary ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                         The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 No safety issues identified,
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021
                                                                                    Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
View HTML
Toggle Summary ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position
ERYTECH Highlights 2021 Milestones and Provides Update on Cash Position                                                           Strong execution and achievement of key milestones in challenging year 2020 Four clinical programs with lead product candidate eryaspase expected to report results
View HTML
Toggle Summary ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer Trial to evaluate safety of eryaspase in combination with FOLFIRINOX for the first-line treatment of pancreatic cancer Trial in Progress (TiP) poster accepted for
View HTML
Toggle Summary ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2020
                                                                                    Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2020. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
Toggle Summary ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
ERYTECH to Present at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event Lyon (France) and Cambridge, MA (U.S.), January 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer
A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a
View HTML
Top